Demonstration of the safety and effectiveness of the RECELL<sup></sup> System combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. 

 -  2019 
<br/><br/>Available online from MWHC library: 1995 - present, Available in print through MWHC library:1996-2007 
<br/><br/> CONCLUSIONS: In combination with widely meshed STSG, RECELL is a safe and effective point-of-care treatment for mixed-depth burns without confluent dermis, achieving short- and long-term healing comparable to standard STSG, while significantly decreasing donor skin use.  Copyright (c) 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.  INTRODUCTION: Split-thickness skin grafts (STSG) are the standard of care (SOC) for burns undergoing autografting but are associated with donor skin site morbidity and limited by the availability of uninjured skin. The RECELL<sup></sup> Autologous Skin Harvesting Device (RECELL<sup></sup> System, or RECELL) was developed for point-of-care preparation and application of a suspension of non-cultured, disaggregated, autologous skin cells, using 1cm<sup>2</sup> of the patient's skin to treat up to 80cm<sup>2</sup> of excised burn.  METHODS: A multi-center, prospective, within-subject controlled, randomized, clinical trial was conducted with 30 subjects to evaluate RECELL in combination with a more widely meshed STSG than a pre-defined SOC meshed STSG (RECELL treatment) for the treatment of mixed-depth burns, including full-thickness. Treatment areas were randomized to receive standard meshed STSG (Control treatment) or RECELL treatment, such that each subject had 1 Control and 1 RECELL treatment area. Effectiveness measures were assessed and included complete wound closure, donor skin use subject satisfaction, and scarring outcomes out to one year following treatment.  RESULTS: At 8 weeks, 85% of the Control-treated wounds were healed compared with 92% of the RECELL-treated wounds, establishing the non-inferiority of RECELL treatment for wound healing. Control-treated and RECELL-treated wounds were similar in mean size; however, mean donor skin use were significantly reduced by 32% with the use of RECELL (p<0.001), establishing the superiority of RECELL treatment for reducing donor skin requirements. Secondary effectiveness and safety outcomes were similar between the treatments. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0305-4179 
<br/><br/><label>Standard No.: </label>10.1016/j.burns.2018.11.002 [doi] S0305-4179(18)30883-0 [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Burns/th [Therapy]<br/>*Cell Transplantation/mt [Methods]<br/>*Skin Transplantation/mt [Methods]<br/>*Wound Healing<br/>Adolescent<br/>Adult<br/>Aged<br/>Child<br/>Equivalence Trials as Topic<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Point-of-Care Systems<br/>Skin/cy [Cytology]<br/>Transplantation, Autologous/mt [Methods]<br/>Treatment Outcome<br/>Young Adult
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Health Research Institute
<br/><br/><label>Index Terms--Occupation: </label><br/>Firefighters' Burn and Surgical Research Laboratory
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article